Review Papers Claim by Claim

Concise critical appraisal (evidence-backed)

1. Accurate synthesis of field strengths: The paper correctly highlights that repurposing can shorten timelines and lower costs relative to de novo development and that computational resources (DrugBank, PDB, ChEMBL) + ML/docking accelerate candidate nomination Paper databases and computational methods.
2. Appropriate use of cautionary examples: The hydroxychloroquine COVID-19 episode is used correctly as a case showing how in vitro signals can fail clinically; the paper cites multiple analyses and the withdrawal of EUA to illustrate risk of over-reliance on early signals HCQ cautionary discussion and COVID-19 RCT meta-analyses context.
3. Methodological blindspots: This is a narrative review — the paper does not present a reproducible, systematic search strategy, inclusion criteria, or PRISMA-style flow; that reduces reproducibility and increases risk of selection/publication bias (authors acknowledge publication bias but do not quantify it). The claim-set is therefore useful but not reproducible by itself Narrative review method.
4. Balance on IP & commercialization: The review correctly identifies patent/IP/pricing barriers as practical hurdles that reduce private-sector incentives — citing analyses of European/US patentability for new medical uses and governmental programs that partially offset this problem IP and repurposing obstacles.
5. Computational claims need calibration: While the review emphasizes docking/ML/knowledge-graphs, the literature shows many computational predictions fail to translate without experimental validation; best practice is multi-step nomination (in silico → biochemical binding → cellular target engagement → PK/PD → RCT). High-performing ML frameworks exist but depend on data quality and careful validation (examples include DeepIPW and graph-based explainers) ML/cheminformatics caveats and Pushpakom 2018 recommendations.

Practical, targeted criticisms (short)

• Missing systematic-method appendix: no reproducible search terms, dates, databases — limits reproducibility and prone to selection bias Lack of systematic method.
• Data/code: no deposited datasets or code accompanying computational claims — prevents re-running or validating claims about integrated in silico workflows.
• Overgeneralization risk: the paper often cites exemplar success stories (daptomycin, dimethyl fumarate, liraglutide) but doesn't quantify overall success rate across disease areas; this can bias reader expectations.
• Recommendation section could be stronger: emphasise standard pipelines (target engagement assays, PK modelling, biomarker-driven RCT design, open-data sharing) and incentivized public–private partnerships for generics repurposing.

What would change my overall conclusion?

Evidence that would materially alter evaluation: (1) a systematic meta-analysis showing repurposed candidates have similar overall Phase II/III failure rates to de novo drugs (would reduce the advantage claim); (2) large-scale, multi-disease prospective pipelines that show computational nomination → biochemical validation → successful RCTs at scale; (3) open datasets and code allowing reproducibility of in silico-to-clinic performance metrics. Absent that, the paper's conclusion that repurposing is a viable acceleration path remains plausible but conditional on rigorous translational steps.

Actionable suggestions to improve the paper (and future repurposing projects)

1. Include a transparent methods appendix (search terms, databases, inclusion/exclusion, dates) and ideally a PRISMA flow.
2. Provide a reproducible data table of candidate examples with evidence level (in vitro binding, target engagement, PK feasibility, RCT evidence) to quantify success/weakness per case.
3. Add an explicit translational pipeline figure: in silico nomination → biochemical binding → cell-based target engagement (eg CETSA) → PK/PD modelling → dose-finding → adaptive RCTs — with recommended go/no-go criteria.
4. Deposit code/notebooks for any in-house computational analyses; archive example docking input/output for top candidates.